Bromfenac ophthalmic solution 0.09 % (BROMDAY™, ISTA Pharmaceuticals, Inc., Irvine, CA) is the first and only once-daily topical ophthalmic non-steroidal anti-inflammatory drug (NSAID) approved by the Food and Drug Administration for the treatment of post-operative pain and inflammation following cataract surgery. Topical NSAIDs are important following surgery to enhance patient comfort and limit inflammation, which may otherwise restrict visual rehabilitation. In a recently published study looking at Early Treatment Diabetic Retinopathy Study (ETDRS) acuities and macular optical computed tomographies (OCTs) in the post-operative period, bromfenac had lower post-operative macular volumes and retinal thicknesses compared with nepafenac, which correlated with a separate retrospective study that found fewer clinical cases of cystoid macular edema (CME) following uneventful phacoemulsification. Since regulatory approval in Japan (2000) and the US (2005 and 2010), bromfenac has been shown to be a safe and effective medication, with more than 26 million ophthalmic uses. Once-daily dosing may confer improvements in compliance and reduce exposure to preservatives, which have been shown to lead to corneal toxicity.